CVOTs cardiovascular outcome trials, T2DM type 2 diabetes mellitus, CVD cardiovascular disease, HF heart failure, CKD chronic kidney disease, HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, GLP-1R GLP-1 receptor, T1DM type 1 diabetes mellitus, GLP-1RAs glucagon-like peptide-1 receptor agonists, DPP-4i DPP-4 inhibitor, HR hazard ratio, CI confidence interval Except for ELIXA and EXSCEL [56, 59], all other major CVOTs point towards cardiovascular benefits of GLP-1RAs [53, 54, 61, 63, 6668]
Archived from the original on 13 December 2021
Yu also cautions that, Its hard to say if drug delivery device manufacturers will keep pace with this growing market, as this market really depends on partnerships made with pharma companies producing GLP 1R agonists
Kim et al
Here at Eden, we offer wide-spanning weight loss solutions including multiple forms of GLP-1